Driven to make a difference
We’re pioneering life-changing therapies for patients with rare diseases and their families.
Inozyme Pharma is a global leader in developing therapies for rare mineralization disorders.
With our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. Two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and defects in these genes lead to abnormal mineralization.
We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies.
With a well-defined regulatory strategy, robust financial backing, and a strong business acumen, we are just getting started.
Experience counts. With decades of clinical, scientific, regulatory, commercial, and financial experience backing our work, we push boundaries to provide hope and transform patient lives.
Thomas O. Carpenter, M.D.
Member of Clinical Advisory Board
Thomas Carpenter is Professor of Pediatrics (Endocrinology) and Orthopedics and Rehabilitation at the Yale School of Medicine. After undergraduate studies at the University of Virginia, Dr. Carpenter earned his medical degree and general pediatrics training at the University of Alabama. His fellowship training in endocrinology at Boston Children’s Hospital began his career-long involvement in clinical research focused on metabolic bone diseases in children.
Dr. Carpenter has been at Yale for more than 30 years and is very active in the Yale Bone Program. He serves as director of Yale’s interdisciplinary Pediatric Metabolic Bone Disease Clinic and is director of the Yale Center for X-Linked Hypophosphatemia, which was founded as a National Institutes of Health (NIH) Center of Research Translation in 2006. The Center concentrates on translational science of XLH and related disorders and serves as a nucleus for the clinical care of families with XLH in the Eastern US. Dr. Carpenter also serves as Medical Director of the Yale Center for Clinical Investigation’s Hospital Research Unit. Dr. Carpenter has served on various editorial boards of pediatric, endocrinology, and bone journals.
Read More +Read Less -Michael A. Levine, M.D.
Chairperson of Clinical Advisory Board
Michael A. Levine is Chief of the Division of Endocrinology and Diabetes and Director of the Center for Bone Health at The Children’s Hospital of Philadelphia. Dr. Levine holds the Lester Baker Endowed Chair in Pediatric Diabetes. His primary clinical interests are endocrine diseases and genetic disorders that affect bone and mineral metabolism.
Dr. Levine has an active laboratory research program that complements and extends his clinical and translational studies. He has identified the molecular basis of several inherited disorders of mineral metabolism and his research interests extend to the molecular basis for embryological development of the parathyroid glands and disorders of vitamin D metabolism. He is a founding Executive Editor for the Journal of Clinical and Translational Science and an Associate Editor of the Journal of Clinical Endocrinology and Metabolism. He is also a member of numerous professional societies, including the American Society for Bone and Mineral Research, the American Society for Clinical Investigation, the Association of American Physicians, and the American Pediatric Society. Dr. Levine is a Fellow of the American College of Physicians and the American Academy of Pediatrics and a Master of the American College of Endocrinology.
Read More +Read Less -Frank Rutsch, M.D.
Member of Clinical Advisory Board
Frank Rutsch is an Associate Professor in Pediatrics at Münster University Children’s Hospital, Münster, Germany. Dr. Rutsch graduated from Münster University Medical School in 1992 and took part in the pediatric residency program in Dresden University and Dortmund Municipal Hospital, Germany. After spending a postdoctoral research fellowship in the Department of Rheumatology and Immunology at the University of California, San Diego, he became the leader of an independent research group at Münster University Children’s Hospital in 2004.
Dr. Rutsch’s main research interests are focused on the discovery of the underlying genetic defects and translational aspects in rare pediatric metabolic and autoimmune disorders. In this respect, with the help of several consortia, his group discovered the genetic cause of generalized arterial calcification of infancy (GACI), Crisponi syndrome, certain defects of intracellular cobalamin metabolism, subtypes of Aicardi-Goutières syndrome and Singleton-Merten syndrome. His current projects include experimental studies in animal models of some of these rare disorders.
Read More +Read Less -
.svg)
